Latent cancer of the prostate
Kishi, K.
Rinsho Byori. Japanese Journal of Clinical Pathology 37(5): 573-576
1989
ISSN/ISBN: 0047-1860 PMID: 2770012 Document Number: 335072
Document emailed within 1 workday
Related Documents
Jarczok, K.; Wolańska-Karut, J.; Lacheta, L.; Huzarski, J.; Urgacz-Ficek, J. 1988: Diagnostic problems in latent forms of cancer of the prostate Polski Tygodnik Lekarski 43(22): 718-720Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Elliott, G.B.; Silverberg, D.S.; Dossetor, J.B.; Muir, C.S. 1977: Latent carcinoma of the prostate in a 24-year-old man receiving cyclophosphamide and azathioprine Canadian Medical Association Journal 116(6): 651-652
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001
Zhu, X-Dong.; Zheng, A.; Wang, Z-Qian.; Shao, Q. 2018: Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population Zhonghua Nan Ke Xue 24(2): 142-146
Wang, W.; Mo, Z.-N. 2010: Advances in prostate-specific membrane antigen targeted therapies for prostate cancer Zhonghua Nan Ke Xue 16(6): 547-551
Bostwick, D.G. 1994: Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer American Journal of Clinical Pathology 102(4 Suppl 1): S31-S37
Fornara, P.; Sturm, W.; Fabricius, P.G.; Schmiedt, E. 1987: Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer Der Urologe. Ausg. a 26(3): 158-161
Schäfer, U.; Micke, O.; Hampel, G.; Brandt, B.; Bovenschulte, A.; Semjonow, A.; Willich, N. 1997: The use of prostate-specific antigen (PSA) for the monitoring of radiation therapy in prostate cancer Anticancer Research 17(4b): 2983-2986
Kelly, W.K.; Slovin, S.; Scher, H.I. 1996: Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer Seminars in Oncology 23(6 Suppl 14: 8-14
Maeda, H.; Arai, Y.; Ishitoya, S.; Okubo, K.; Aoki, Y.; Okada, T.; Maekawa, S. 1998: Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 44(5): 307-311
Erdamar, S.; Yang, G.; Harper, J.W.; Lu, X.; Kattan, M.W.; Thompson, T.C.; Wheeler, T.M. 1999: Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 12(8): 751-755